Table 1.
Baseline Demographic and Clinical Characteristics of IBD Patients.
| Variables | CD (n=201) | UC (n=100) | HC (n=178) | |||
|---|---|---|---|---|---|---|
| Females (%) | 71 (35.32%) | 38 (38%) | 63 (35.39%) | |||
| Age at diagnosis (years) | 35.14±14.21 (13, 74) | 45.87±17.20 (17, 83) | 47.36±10.78 (24, 80) | |||
| A1 (≤16 years): 14 (6.97%) | ||||||
| A2 (17-40 years): 122 (60.70%) | ||||||
| A3>40 years: 65 (32.34%) | ||||||
| BMI (kg/m2) | 19.94±3.38 (13.02, 29.39) | 21.65±3.40 (13.22, 28.28) | ||||
| Duration (months) | 44.41±53.90 (0.25, 360) | 34.56±36.50 (0.5, 168) | ||||
| Location of disease | L1-Terminal ileum: 43 (21.39%) | E1-Proctitis: 10 (10%) | ||||
| L2-Colon: 49 (24.38%) | E2-Left-sided colitis: 27 (27%) | |||||
| L3-Ileocolon: 105 (52.24%) | E3-Extensive/pancolitis: 63 (63%) | |||||
| L4-Upper gastrointenstina: 8 (3.98%) | ||||||
| L2+L4: 2 (1%) | ||||||
| L3+L4: 2 (1%) | ||||||
| Disease behavior | B1-Non stricturing, non penetrating : 91 (45.27%) | |||||
| B2-Stricturing: 83 (41.29%) | ||||||
| B3-Penetrating: 27 (13.43%) | ||||||
| P-Perianal disease: 15 (7.46%) | ||||||
| Disease activity | Remission: 63 (31.34%) | Remission: 18 (18%) | ||||
| Active: 138 (68.66%) | Mild: 39 (39%) | |||||
| Moderate: 25 (25%) | ||||||
| Severe: 18 (18%) | ||||||
| Incipient/Recurrence | Incipient: 38 (38%) | |||||
| Recurrence: 62 (62%) | ||||||
| Treatment | ||||||
| 5-ASA | 142 (70.65%) | 97 (97%) | ||||
| Azathioprine | 76 (37.62%) | 17 (17%) | ||||
| Corticosteroids | 82 (40.59%) | 75 (75%) | ||||
| IFX | 101 (50.25%) | 5 (5%) | ||||
| Enteral nutrition | 29 (14.36%) | 6 (6%) | ||||
| Surgical intervention | 58 (28.71%) | 1 (1%) |
CD: Crohn's disease, UC: ulcerative colitis, HC: healthy controls, BMI: body mass index, 5-ASA: 5-aminosalicylate, IFX: infliximab